Bayer sells oncology asset Stivarga for €375m
German global life science and pharmaceutical company Bayer has divested its established oncology asset Stivarga to the German pharmaceutical firm Grünenthal for a total consideration of up to €375m. The transaction, announced in September 2026, involves the transfer of rights for Stivarga, also known as regorafenib, which is a once daily oral multikinase inhibitor approved in more than 90 markets…
Bayer buying Perfuse Therapeutics for up to $2.45bn
Germany-based multinational life science company Bayer is to fully acquire San Francisco based biopharmaceutical firm Perfuse Therapeutics for a total potential value of up to $2.45bn, signalling a robust return to strategic merger and acquisition activity. The transaction comprises a $300m upfront cash payment, alongside up to $2.15bn in contingent payments linked to specific development, regulatory, and commercial milestones. The…